[HTML][HTML] Pharmacological and non-pharmacological treatments of sleep disorders in Parkinson's disease

R Taximaimaiti, X Luo, XP Wang - Current Neuropharmacology, 2021 - ncbi.nlm.nih.gov
Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease
(PD). It can cause a notable decrease in quality of life and functioning in PD patients, as well …

An overview of sleep and circadian dysfunction in Parkinson's disease

S Mantovani, SS Smith, R Gordon… - Journal of Sleep …, 2018 - Wiley Online Library
Sleep and circadian alterations are amongst the very first symptoms experienced in
Parkinson's disease, and sleep alterations are present in the majority of patients with overt …

Pain management in patients with Parkinson's disease: challenges and solutions

O Skogar, J Lokk - Journal of multidisciplinary healthcare, 2016 - Taylor & Francis
This review focuses on the diagnosis and management of Parkinson-related pain which is
one of the more frequently reported nonmotor symptoms in Parkinson's disease (PD), which …

The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models

F Faivre, A Joshi, E Bezard, M Barrot - Neuroscience & Biobehavioral …, 2019 - Elsevier
Parkinson's disease is a neurodegenerative disease leading to the loss of midbrain
dopamine neurons. It is well known and characterized by motor symptoms that are …

Restless legs syndrome and Parkinson disease: a causal relationship between the two disorders?

L Ferini-Strambi, G Carli, F Casoni, A Galbiati - Frontiers in neurology, 2018 - frontiersin.org
Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a common sleep related
movement disorder that can be idiopathic or occurs in comorbidity with other medical …

Psychological considerations in the assessment and treatment of pain in neurorehabilitation and psychological factors predictive of therapeutic response: evidence …

G Castelnuovo, EM Giusti, GM Manzoni… - Frontiers in …, 2016 - frontiersin.org
Background: In order to provide effective care to patients suffering from chronic pain
secondary to neurological diseases, health professionals must appraise the role of the …

The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques

R Depoortere, TH Johnston, SH Fox… - Parkinsonism & related …, 2020 - Elsevier
Background Long-term treatment of Parkinson's disease (PD) with l-DOPA typically leads to
development of l-DOPA induced dyskinesia (LID). Amantadine, an NMDA antagonist …

Disability from pain directly correlated with depression in Parkinson's disease

AQ Rana, ARM Qureshi, N Rahman… - Clinical neurology and …, 2017 - Elsevier
Objective Parkinson's disease (PD) is a progressively debilitating disorder resulting in
reduced quality of life (QoL). Along with the motor symptoms of PD, non-motor symptoms of …

[HTML][HTML] The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets

R Fisher, A Hikima, R Morris, MJ Jackson, S Rose… - …, 2020 - Elsevier
Abstract l-DOPA is the gold-standard pharmacotherapy for treatment of Parkinson's disease
(PD) but can lead to the appearance of troubling dyskinesia which are attributable to 'false …

Relationship of nocturnal sleep dysfunction and pain subtypes in Parkinson's disease

P Martinez‐Martin, AM Rizos… - Movement disorders …, 2019 - Wiley Online Library
Background Little research has been conducted regarding the relationship between sleep
disorders and different pain types in Parkinson's disease (PD). Objective To explore the …